Isoindolone M1 receptor positive allosteric modulators
View Patent ↗The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
1. A compound of formula (I):
and pharmaceutically acceptable salts thereof, wherein
Y and Z independently represent CH, or N, provided that they both are not N at the same time,
W represents aryl, pyridyl, or oxopiperidinyl, optionally substituted with one or more of R x ;
R is selected from the group consisting of hydrogen, (CHR 2 ) n C 3-10 cycloalkyl, (CHR 2 ) n C 6-10 aryl, (CHR 2 ) n C 5-10 heterocycle, said cycloalkyl, aryl, and heterocyclyl optionally substituted with 1 to 3 groups of R y ;
R 1 and R 3 independently represent H, C 1-6 alkyl, C 2-6 alkenyl, (CH 2 ) n C 6-10 aryl, (CH 2 ) n —O—(CH 2 ) n C 6-10 aryl, said alkyl, alkenyl optionally substituted with 1 to 3 groups of OH, CF 3 , halo, or N(R 2 ) 2 , or
R 1 and R 3 together with the carbon atom they are attached form a 3-6 cycloalkyl;
R x is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, halogen, OR 2 , (CHR 2 ) n C 5-10 heterocyclyl, (CHR 2 ) n C 6-10 aryl, —O(CHR 2 ) n C 6-10 aryl, CN, SR 2 , N(R 2 ) 2 , (CH 2 ) n CF 3 , —O(CH 2 ) n CF 3 , C 3-6 cycloalkyl, said heterocyclyl and aryl optionally substituted with 1 to 3 groups of C 1-6 alkyl, halogen, hydroxyl, (CH 2 ) n CF 3 , or CN,
R y is selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, halogen, COOR 2 , OR 2 , CN, SR 2 , N(R 2 ) 2 , and (CH 2 ) n CF 3 ,
R 2 is selected from the group consisting of hydrogen, or —C 1-6 alkyl, and
n is 0, 1 or 2.
2. The compound of claim 1 wherein W is pyridyl, and pharmaceutically acceptable salts thereof.
3. The compound of claim 1 wherein W is phenyl, and pharmaceutically acceptable salts thereof.
4. The compound of claim 1 wherein R is C 3-10 cycloalkyl optionally substituted with 1 to 3 groups of R y , and pharmaceutically acceptable salts thereof.
5. The compound according to claim 4 wherein R is cyclohexyl or cyclohexenyl, both optionally substituted with 1 to 3 groups of R y , and pharmaceutically acceptable salts thereof.
6. The compound of claim 1 wherein R is (CHR 2 ) n C 5-10 heterocycle, optionally substituted with 1 to 3 groups of R y , and pharmaceutically acceptable salts thereof.
7. The compound according to claim 6 wherein R is pyranyl, tetrahydropyranyl, or pyridyl, all optionally substituted with 1 to 3 groups of R y , and pharmaceutically acceptable salts thereof.
8. The compound according to claim 1 wherein R is (CHR 12 ) n C 6-10 aryl, optionally substituted with 1 to 3 groups of R y , and pharmaceutically acceptable salts thereof.
9. The compound according to claim 8 wherein R is phenyl optionally substituted with 1 to 3 groups of R y , and pharmaceutically acceptable salts thereof.
10. The compound according to claim 1 represented by structural formula II:
and pharmaceutically acceptable salts thereof,
wherein R is selected from the group consisting of cyclohexyl or cyclohexenyl, pyranyl, tetrahydropyranyl, pyridyl and phenyl all of which are optionally substituted with 1 to 3 groups of R y , W is phenyl or pyridyl and Y and Z are both CH, Y is N and Z is CH, or Y is CH and Z is N.
11. The compound of claim 10 represented by structural formula IIIa:
and pharmaceutically acceptable salts thereof,
wherein W is phenyl or pyridyl, Y and Z are both CH, Y is N and Z is CH, or Y is CH and Z is N, R y is OH or H, and R x is selected from the group consisting of hydroxyl, methoxy, halogen, CF 3 , morpholino, S-methyl, methyl, ethyl, CN, ethylene, OCH 2 CF 3 , pyrazolyl, and methylpyrazolyl.
12. The compound of claim 10 represented by structural formula IVa:
and pharmaceutically acceptable salts thereof,
wherein W is phenyl or pyridyl, Y and Z are both CH, Y is N and Z is CH, or Y is CH and Z is N, R y is OH or H, and R x is selected from the group consisting of hydroxyl, methoxy, halogen, CF 3 , morpholino, S-methyl, methyl, ethyl, CN, ethylene, OCH 2 CF 3 , pyrazolyl, and methylpyrazolyl.
13. The compound of claim 10 represented by structural formula V:
and pharmaceutically acceptable salts thereof,
wherein P is pyridyl, W is pyridyl or phenyl, Y and Z are both CH or Y is N and Z is CH, R x is selected from the group consisting of hydroxyl, methoxy, halogen, CF 3 , morpholino, S-methyl, methyl, ethyl, CN, ethylene, OCH 2 CF 3 , pyrazolyl, and methylpyrazolyl and R y is selected from the group consisting of (CH 2 ) n OH, COOR 2 , NH 2 , methoxy, halogen, CF 3 , morpholino, S-methyl, methyl, ethyl, and CN.
14. The compound of claim 10 represented by structural formula VI:
and pharmaceutically acceptable salts thereof,
wherein P is pyridyl, W is pyridyl or phenyl, Y and Z are both CH or Y is N and Z is CH, R x is selected from the group consisting of hydroxyl, methoxy, halogen, CF 3 , morpholino, S-methyl, methyl, ethyl, CN, ethylene, OCH 2 CF 3 , pyrazolyl, and methylpyrazolyl and R y is selected from the group consisting of (CH 2 ) n OH, COOR 2 , NH 2 , methoxy, halogen, CF 3 , morpholino, S-methyl, methyl, ethyl, and CN.
15. A compound of formula (I) of claim 1 which is found in Table 1 as well as those listed immediately below:
2-[(1S,2S)-2-Hydroxycyclohexyl]-5-(4-methoxybenzyl)-1,2-dihydro-3H-benzo[e]isoindol-3-one;
2-[(1S,2S)-2-Hydroxycyclohexyl]-5-[(6-methylpyridin-3-yl)methyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one,
2-[(1S,2S)-2-Hydroxycyclohexyl]-5-[(6-vinylpyridin-3-yl)methyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one
5-[(6-Chloropyridin-3-yl)methyl]-2-[(2S)-2-fluorocyclohexyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one
5-[(6-Chloropyridin-3-yl)methyl]-2-cyclohex-2-en-1-yl-1,2-dihydro-3H-benzo[e]isoindol-3-one
2-[(1S,2S)-2-Hydroxycyclohexyl]-5-(pyridin-3-ylmethyl)-1,2-dihydro-3H-benzo[e]isoindol-3-one
2-[(1S,2S)-2-Hydroxycyclohexyl]-5-[(6-morpholin-4-ylpyridin-3-yl)methyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one
5-[(6-Chloropyridin-3-yl)methyl]-2-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]-1,2-dihydro-3H-benzo[e]isoindol-3-one
5-({2-[(1S,2S)-2-Hydroxycyclohexyl]-3-oxo-2,3-dihydro-1H-benzo[e]isoindol-5-yl}methyl)pyridine-2-carbonitrile
2-[(1S,2S)-2-Hydroxycyclohexyl]-5-{[6-(methylthio)pyridine-3-yl]methyl}-1,2-dihydro-3H-benzo[e]isoindol-3-one
2-[(3S,4S)-4-Hydroxytetrahydro-2H-pyran-3-yl]-5-[(6-methoxypyridin-3-yl)methyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one
2-O-Acetyl-1,5-anhydro-3,4-dideoxy-3-{3-oxo-5-[(6-oxo-1,6-dihydroyridin-3-yl)methyl]-1,3-dihydro-2H-benzo[e]isoindol-2-yl)-L-threo-pentitol
1,5-Anhydro-2,3-dideoxy-3-{3-oxo-5-[(6-oxo-1,6-dihydropyridin-3-yl)methyl]-1,3-dihydro-2H-benzo[e]isoindol-2-yl}-L-threo-pentitol
5-[(6-Methoxypyridin-3-yl)methyl]-2-[3-(trifluoromethyl)pyridin-2-yl]-1,2-dihydro-3H-benzo[e]isoindol-3-one
(±)-5-[(6-Chloropyridin-3-yl)methyl]-2-(2-fluorophenyl)-1-methyl-1,2-dihydro-3H-benzo[e]isoinol-3-one
(±)-5-[(6-Chloropyridin-3-yl)methyl]-2-[trans-2-hydroxycyclohexyl]-1,2-dihydro-3H-pyrrolo[3,4-c]isoquinoline-3-one
(±)-2-[trans-2-Hydroxycyclohexyl]-5-{[6-(1H-pyrazol-1-yl)pyridine-3-yl]methyl}-1,2-dihydro-3H-pyrrolo[3,4-c]isoquinoline-3-one
8-[(1S,2S)-2-Hydroxycyclohexyl]-5-[(6-methoxypyridin-3-yl)methyl]-9,9-dimethyl-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
5-{[6-Benzyloxy)pyridine-3-yl]methyl}-8-[(1S,2S)-2-hydroxycyclohexyl]-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
8-[(1S,2S)-2-Hydroxycyclohexyl]-5-[(6-oxopiperidin-3-yl)methyl]-3,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
5-[(6-Chloropyridin-3-yl)methyl]-9-(2,3-dihydroxypropyl)-8-[(1S,2S)-2-hydroxycyclohexyl]-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
8-[(1S,2S)-2-Hydroxycyclohexyl]-5-[(6-oxopiperidin-3-yl)methyl]-3,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
5-[(6-Chloropyridin-3-yl)methyl]-9-(2,3-dihydroxypropyl)-8-[(1S,2S)-2-hydroxycyclohexyl]-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
{5-[(6-Chloropyridin-3-yl)methyl]-8-[(1S,2S)-2-hydroxycyclohexyl]-7-oxo-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-9-yl}acetaldehyde
5-[(6-Chloropyridin-3-yl)methyl]-9-[2-(dimethylamino)ethyl]-8-[(1S,2S)-2-hydroxycyclohexyl]-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
5-[(6-Chloropyridin-3-yl)methyl]-8-[(1S,2S)-2-hydroxycyclohexyl]-9-(2-hydroxyethyl)-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one
5-[(6-Cyclopropylpyridin-3-yl)methyl]-8-[(1S,2S)-2-hydroxycyclohexyl-8,9-dihydro-7H-pyrrolo[3,4-h]quinolin-7-one,
and pharmaceutically acceptable salts thereof.
16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. A method of treating a disease or disorder mediated by the muscarinic M1 receptor, wherein said disease or disorder is selected from the group consisting of Alzheimer's disease, schizophrenia, pain or sleep disorders in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.